Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:16 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Peripheral Blood Stem Cell Collection From Patients With Sickle Cell Disease (SCD) Using Plerixafor
NCT04817345 · St. Jude Children's Research Hospital · PHASE2 · withdrawn · last registry update 2023-04-07 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The safety and efficacy of plerixafor in adult and pediatric SCD patients was an unknown when we started. A lot more data from therapeutic trials is available. We feel that recruiting patients without a therapeutic option isn't ethically justifiable.” | – | Registry record, St. Jude Children's Research Hospital |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CXCR4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-02-20Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Cemiplimab + Plerixafor (NCT04177810)
- 2023-11-01Also stopped (terminated): Jonsson Comprehensive Cancer Center, Aldesleukin + Busulfan (NCT03240861)
- 2023-11-01Results posted on the registry: Spexis AG, Eribulin + Balixafortide (NCT03786094)
- 2023-11-01Also stopped (terminated): Spexis AG, Eribulin + Balixafortide (NCT03786094)
- 2023-09-28Phase 3 first posted: X4 Pharmaceuticals, Mavorixafor + Placebo (NCT06056297)
- 2023-09-14Results posted on the registry: Center for International Blood and Marrow Transplant Research, Plerixafor (NCT01696461)
- 2023-04-10Also stopped (withdrawn): 4Living Biotech, Plerixafor 20 MG/ML [Mozobil] (NCT05411575)
- 2023-04-07Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), Plerixafor + G-CSF (NCT02231879)
- 2023-03-20Also stopped (withdrawn): MedSIR, POL6326 + Eribulin (NCT04826016)
- 2023-01-30Also stopped (terminated): Dana-Farber Cancer Institute, Cyclophosphamide + Doxorubicin (NCT01746173)
- 2022-12-29Results posted on the registry: X4 Pharmaceuticals, X4P-001 + Nivolumab (NCT02923531)
- 2022-12-29Also stopped (terminated): X4 Pharmaceuticals, X4P-001 + Nivolumab (NCT02923531)
- 2022-10-14Also stopped (withdrawn): Albert Einstein College of Medicine, 153Sm-DOTMP + Calcium Carbonate (NCT03612466)
- 2022-09-10Results posted on the registry: Surbhi Sidana, MD, MGTA-145 + Plerixafor (NCT04552743)
- 2022-05-18Also stopped (terminated): Fred Hutchinson Cancer Center, Carmustine + Filgrastim (NCT00669669)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision